Los Angeles Capital Management’s Sutro Biopharma STRO Stock Holding History

Los Angeles Capital Management’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-6,832	Closed	-$237K	–	1230
2023 Q3	$237K	Buy	6,832 +1,180	+21%	+$51.4K	﹤0.01%	1028
2023 Q2	$263K	Buy	5,652 +1,067	+23%	+$53.1K	﹤0.01%	1044
2023 Q1	$212K	Sell	4,585 -1,727	-27%	-$110K	﹤0.01%	1115
2022 Q4	$510K	Sell	6,312 -556	-8%	-$38.6K	﹤0.01%	897
2022 Q3	$381K	Hold	6,868	–	–	﹤0.01%	1001
2022 Q2	$358K	Buy	6,868 +2,768	+68%	+$155K	﹤0.01%	1093
2022 Q1	$337K	Hold	4,100	–	–	﹤0.01%	1191
2021 Q4	$610K	Hold	4,100	–	–	﹤0.01%	911
2021 Q3	$775K	Sell	4,100 -275	-6%	-$52.3K	﹤0.01%	863
2021 Q2	$813K	Buy	+4,375	New	+$856K	﹤0.01%	943
2020 Q4	–	Sell	-2,964	Closed	-$298K	–	1548
2020 Q3	$298K	Buy	2,964 +579	+24%	+$54.7K	﹤0.01%	1272
2020 Q2	$185K	Buy	+2,385	New	+$229K	﹤0.01%	1406

Other funds holding STRO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Los Angeles Capital Management's STRO Position: Q4 2023 in Review

Los Angeles Capital Management sold out of Sutro Biopharma (STRO) in Q4 2023, closing a stake of 6,832 shares — an estimated $237K sold.

Los Angeles Capital Management first reported a position in STRO in Q2 2020 and held it in 12 quarters. The position peaked at $813K in Q2 2021. 114 funds tracked by Wall St. Rank hold STRO as of Q4 2023.

Los Angeles Capital Management reported no remaining Sutro Biopharma position as of Q4 2023 after selling out during the quarter.
Los Angeles Capital Management sold 6,832 Sutro Biopharma shares in Q4 2023, an estimated $237K.
Los Angeles Capital Management first reported a position in Sutro Biopharma in Q2 2020 and held it in 12 quarters.
Los Angeles Capital Management's Sutro Biopharma position peaked at $813K in Q2 2021.
114 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2023.

Based on Los Angeles Capital Management's 13F filing for Q4 2023, filed 6 Feb 2024.